Bristol-Myers buying Inhibitex for $2.5 billion
January 08, 2012 at 11:05 AM EST
Bristol-Myers Squibb purchasing Inhibitex, a specialist in hepatitis C treatments, for $2.5 billion
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.